Anti-CCR5 agents and methods of treatment that block cancer metastasis or enhance cell death induced by DNA-damaging chemotherapy
CCR5-binding agents like leronlimab, when combined with DNA-damaging chemotherapy, provide a targeted approach to block breast cancer metastasis and enhance chemotherapy efficacy while minimizing side effects.
Patent Information
- Application Number
- JP2021558834
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-01
- Filing Date
- 2020-04-01
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2040-04-01
AI Technical Summary
Current treatments for breast cancer, particularly metastatic breast cancer, lack specificity in targeting metastatic processes, and existing anti-CCR5 agents may have immunosuppressive effects or unintended side effects, necessitating the development of targeted therapies that inhibit CCR5 signaling without adverse consequences.
The use of CCR5-binding agents, such as leronlimab (PRO140), in conjunction with DNA-damaging chemotherapy, selectively targets CCR5 receptors to block metastasis and enhance the efficacy of chemotherapy by reducing unintended side effects.
CCR5-binding agents like leronlimab effectively block breast cancer metastasis, enhance the cell-killing potential of DNA-damaging chemotherapies, and reduce tumor volume, offering a targeted treatment with fewer side effects.
Smart Images

Figure 0007583736000005 
Figure 0007583736000006 
Figure 0007583736000007
Abstract
Description
[Background technology]
[0001] In cancer, studies have shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. And published studies have shown that blocking CCR5 can reduce tumor metastasis in laboratory and animal models of aggressive breast and prostate cancer.
[0002] Several studies indicate that CCR5 signaling has antitumor effects, acts as a costimulatory molecule for T cell activation, and increases T cell chemotaxis to the tumor microenvironment. See Gao et al., CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells, OPEN BIOL., 6: 160122 (2016);Gonzalez-Martin et al., CCR5 in cancer immunotherapy: More than an “attractive” receptor for T cells, ONCOlMMUNOLOGY, 1: 106-108 (2012). However, evidence also suggests that CCL5 / CCR5 axis signaling may be preferentially activated in certain types of cancer, such as breast and prostate cancer, and that such signaling facilitates disease progression. For example, several studies indicate that cancer cells can overexpress CCL5, CCR5, or both, likely contributing to their growth and proliferation through the effect of CCR5 signaling on the mechanistic target of rapamycin (mTOR). See Gao et al., CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells, OPEN BIOL., 6: 160122 (2016);Chow and Luster, Chemokines in Cancer, CANCER IMMUNOL. RES., 2(12): 1125-1131 (2014);See also Singh et al., Expression of CCR5 and its ligand CCL5 in pancreatic cancer (Abstract), J IMMUNOL, 196(1 Supplement): 51.3 (2016).In addition, several immunosuppressive immune cells, including regulatory T cells (Tregs) and myeloid-derived suppressive cells (MDSCs), express CCR5, suggesting another pathway by which CCR5 signaling may contribute to tumor growth. Mukaida, CCR5 antagonist, an ally to fight against metastatic colorectal cancer, TRANSLATIONAL CANCER RESEARCH, 5(Supp. 2): S309-S312 (2016). Furthermore, cancer cells in the tumor microenvironment express CD4. + and CD8 + It has been reported that CCL5 production by T cells can be exploited to lead to increased tumor growth and tumor cell progression. Halama et al., Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients, CANCER CELL, 29: 587-601 (2016).
[0003] Preliminary work has been done with anti-CCR5 binding agents that alter CCL5 / CCR5 signaling in several cancer types. Sicoli et al., CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene-Transformed Metastatic Prostate Cancer Cell Lines, CANCER RES., 74(23): 7103-7114 (2014);Velasco-Velazquez et al., The CCL5 / CCR5 Axis Promotes Metastasis In Basal Breast Cancer, ONCOIMMUNOLOGY, 2(4): e23660 (2013);Velasco-Velazquez et al., CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells, CANCER RES., 72(15): 3839-3850 (2012). There are various compounds that inhibit, block, block, alter or modify the CCR5 / CCL5 receptor / ligand axis (i.e., the CCR5 receptor / CCL5 ligand axis). Many of these compounds were developed for the treatment of HIV-1. It is also known to bind to the CCR5 receptor and share some binding commonalities with CCL5. Such compounds include extracellular or transmembrane CCR5 binding agents, such as PRO140 (extracellular) and maraviroc (transmembrane), as well as other compounds such as vicriviroc, aplaviroc, SCH-C, and TAK-779, and antibodies such as PA14, 2D7, RoAb13, RoAb14, 45523, and the like. It has been found that the most potently antiviral anti-CCR5 monoclonal antibodies, including PRO140, bind to the CCR5 receptor amino acid residues on EL2 alone or in combination with the Nt residue. It has also been determined that the CCR5 receptor binding site of anti-CCR5 monoclonal antibodies is distinct from that of small molecule CCR5 antagonists.That is, available small molecule CCR5 antagonists such as maraviroc bind to the hydrophobic cavity formed by the transmembrane helices, i.e., not the extracellular Nt or loop regions. The amino acid residue E283 on the seventh transmembrane region has been specifically identified as the principle site of interaction for small molecules, and maraviroc and vicriviroc have been found to bind to the same set of CCR5 receptor amino acids. Olson et al., CCR5 Monoclonal Antibodies for HIV-1 Therapy, CURR. OPIN. HIV AIDS, March, 4(2): 104-111 (2009). However, it has also been reported that CCL5 ligands and maraviroc dock onto the CCR5 receptor by sharing two receptor sites: Nt and ECL2, and that synthetic CCL5-derived peptides can also be used to block the CCR5 receptor. Secchi et al., Combination of the CCL5-Derived Peptide R4.0 with Different HIV-1 Blockers Reveals Wide Target Compatibility and Synergic Cobinding to CCR5, ANTIMICROB AGENTS CHEMOTHER., 58(10): 6215-6223 (2014).
[0004] In some cases, CCL5 expression, which is associated with immune cell activation, may be exploited by cancer cells in the tumor microenvironment, and blocking CCR5 signaling with inhibitors such as maraviroc may have an antitumor effect. In a study of human colon cancer liver metastases, CD4 + and CD8 +T cells express CCL5, which is associated with T cell exhaustion, tumor growth, invasive tumor cell behavior, and increased production of matrix metalloproteinases by tumor-associated macrophages. Halama et al., Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients, CANCER CELL, 29: 587-601 (2016). Inhibiting CCL5 with maraviroc led to repolarization of tumor-associated macrophages and tumor cell death. Halama et al. (2016).
[0005] However, inhibition of CCR5 signaling may also have immunosuppressive effects. In vitro studies have been conducted to examine the effect of CCR5 receptor blockade by maraviroc on activated human T cells on possible immunological mechanisms. It was found that blocking CCR5 by maraviroc could not only block the CCR5 and CCR2 internalization process induced by CCL5 and CCL2, but also inhibit T cell chemotactic activity toward their corresponding ligands, respectively. Furthermore, blocking CCR5 by high doses of maraviroc tends to reduce the production of TNF-α and IFN-γ. It was also noted that the effect of maraviroc on CCR5 is temporary and reversible. Yuan et al., In Vitro Immunological Effects of Blocking CCR5 on T Cells, INFLAMMATION, 38(2): 902-910 (2015);Arberas et al., In vitro effects of the CCR5 inhibitor maraviroc on human T cell function, J. ANTIMICROB. CHEMOTHER., 68(3): 577-586 (2013).
[0006] In view of the multiple and sometimes contradictory roles of CCR5 signaling in contributing to tumorigenesis, there is a need for competitive inhibitors against CCR5 receptor and methods of use that can be used to inhibit, attenuate, block, block, modify or alter the CCR5 / CCL5 receptor / ligand axis for therapeutic purposes without inducing unintended side effects, or to reduce the impact of unintended side effects.Furthermore, there is a need for such competitive inhibitors against CCR5 receptor and methods of use that cause fewer and less severe side effects, are more durable, and facilitate improved patient compliance due to reduced dosing requirements and improved patient experience (due to fewer undesirable side effects), including side effects caused by the competitive inhibitor itself.Optimal therapeutic modalities using the CCL5 / CCR5 axis as a therapeutic target will require reconciling two opposing demands: the need to inhibit the harmful involvement of CCL5 and CCR5 in certain malignancies, while preserving their potentially beneficial activities in immunity.
[0007] Breast cancer remains the most common solid tumor affecting women and is the second leading cause of cancer-related death in women. Metastasis is the primary cause of death in patients with breast cancer. Currently, there are no approved treatments that are specifically directed at the metastatic process.
[0008] Additionally, 10 to 15 percent of breast cancer patients have triple-negative breast cancer (TNBC), which is defined by the lack of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor-2 (HER-2) expression, which are known targets of endocrine therapy and anti-HER2 agents, respectively. Approximately 70-84% of TNBC are basal-like; conversely, approximately 70% of basal-like tumors are TNBC (Nielson 2004, Prat 2011, Prat 2013).
[0009] Chemotherapy remains the main treatment option for TNBC patients, and the standard treatment is surgery with adjuvant chemotherapy and radiation therapy. Although TNBC responds better to chemotherapy drugs such as taxanes and anthracyclines than other subtypes of breast cancer, the prognosis remains poor. As a variant, neoadjuvant chemotherapy is frequently used for triple-negative breast cancer [Hudis 2011]. This allows for higher rates of breast-conserving surgery, and assessing response to chemotherapy provides important clues about the individual responsiveness of a particular cancer to chemotherapy.
[0010] Due to the loss of target receptors such as ER, PGR, and HER-2, patients with TNBC do not benefit from hormonal therapy or trastuzumab-based treatment. Hence, surgery and chemotherapy, individually or in combination, appear to be the only available modalities. To date, there are multiple approaches attempting to improve the care of patients with triple-negative breast cancer, including platinum, targeted EGFR and VEGF inhibitors, and DNA-damaging agents such as PARP inhibitors; however, none have been as clinically successful as expected, requiring more targeted therapies to be developed and explored [Aysola 2013]. Hence, metastatic TNBC is a complex disease with unmet needs and unestablished treatment regimens in clinical practice.
[0011] Improved cancer treatments directed specifically at the metastatic process, such as the administration of CCR5-binding agents in conjunction with currently available therapies such as DNA damaging agents, are needed to provide meaningful improvements in patient treatment options. Summary of the Invention
[0012] The present disclosure relates to the use of DNA damaging agents and Leronlimab (PRO140) or other anti-CCR5 agents to treat or prevent cancer metastasis and enhance the cell killing ability of DNA damaging agents by selectively targeting CCR5 receptors. The present disclosure relates to the use of DNA damaging agents and Leronlimab (PRO140) or other anti-CCR5 agents to treat or prevent cancer metastasis, and to reduce circulating tumor cells (CTCs) or putative metastatic tumor cells in peripheral blood after treatment, reduce CCR5 expression on cancer-associated cells after treatment, and reduce the volume of tumor size after treatment. The present disclosure can be used to treat or prevent patients with cancer, particularly patients with metastatic CCR5+ cancer.
[0013] As shown in the xenograft model described herein, leronlimab can effectively block CCR5-positive breast cancer metastasis.Mouse xenograft models are also provided, which show that by reducing the ability of breast cancer cells to metastasize, tumors are more contained.In addition, it is shown that leronlimab can potentially provide more time for standard DNA-damaging chemotherapy to work, potentially providing significantly improved efficacy of existing cancer treatments with fewer side effects.In other words, leronlimab enhances the effect of DNA-damaging drugs to kill cancer cells. [Brief description of the drawings]
[0014] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Figure 1A] Leronlimab binds to CCR5 on human breast cancer cells. [Figure 1B] Leronlimab binds to CCR5 on human breast cancer cells. [Figure 2A] PRO140 blocks signaling mediated by human CCR5 in human breast cancer cells. [Figure 2B]PRO140 blocks signaling mediated by human CCR5 in human breast cancer cells. [Figure 2C] PRO140 blocks signaling mediated by human CCR5 in human breast cancer cells. [Figure 2D] PRO140 blocks signaling mediated by human CCR5 in human breast cancer cells. [Figure 3A] Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix. [Figure 3B] Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix. [Figure 3C] Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix. [Figure 3D] Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix. [Figure 4A] Leronlimab blocks breast cancer metastasis in mice. [Figure 4B] Leronlimab blocks breast cancer metastasis in mice. [Diagram 5] Leronlimab enhances cell death induced by doxorubicin, a chemotherapy drug that induces DNA damage. [Figure 6] Figures 6A-6C show immunohistochemical staining for CCR5 of tissue samples from subjects with triple-negative breast cancer. Figure 6A shows a representative image of IHC for CCR5. Immunohistochemical analysis of archival tissue showed a high predominance of CCR5+ tumor-infiltrating leukocytes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] Increased CCR5 expression is indicative of a disease state in several cancers, including but not limited to breast cancer.
[0016] Metastasis is the main cause of death in patients with breast cancer, but currently there is no available treatment that targets the metastatic process.Therefore, there is a need for better treatment for metastatic cancer, including metastatic breast cancer.A method is presented herein for treating a subject with metastatic breast cancer by administering an effective amount of a CCR5 binding agent, such as leronlimab, to the subject.In particular, the present disclosure relates to the use of leronlimab (PRO140) or other anti-CCR5 agents to selectively target the CCR5 receptor in a subject with cancer, thereby treating, reducing, preventing, or blocking cancer metastasis and / or enhancing the cell-killing ability of DNA-damaging chemotherapy.
[0017] Preclinical and clinical data suggest that chemokine receptors and their ligands, also referred to as chemoattractants or chemotactic cytokines, are involved in the process of cancer cell tropism by specific organs [Moser, 2001][Neagu, 2015][Velasco-Velazquez, 2012]. CC chemokine receptor type 5 (CCR5) is selectively re-expressed on the surface of tumor cells during dedifferentiation and transformation processes (velasco-velazquez-2012). Velasco-Velazquez et al. evaluated the analysis of a combined microarray database containing 2,254 breast cancer samples and showed that the expression of CCL5 / CCR5 is higher in the basal subtype of breast cancer (more than 58% of samples) compared to the luminal subtype [Velasco-Velazquez, 2012]. CCR5 has been shown to be sufficient to induce invasiveness and metastasis of breast cancer cells in vitro, which is blocked by CCR5 inhibitors [Velasco-Velazquez, 2012]. CCR5 inhibitors such as maraviroc effectively blocked lung metastasis in breast cancer tumor models.
[0018] CCR5 binding drugs, including leronlimab (PRO140), show significant reduction in tumor volume in breast cancer tumor models. Another cancer hallmark in which CCR5 presents a possible role is the DNA repair pathway. This cancer hallmark attenuates apoptosis and contributes to chemotherapy resistance and tumor cell immortality. Studies have correlated altered expression of CC chemokine ligand type 5 (CCL5) with disease progression in patients with breast cancer [Luboshits, 1999][Niwa, 2001][Zhang, 2009].
[0019] CCR5-binding drugs, such as the antagonists maraviroc and vicriviroc, dramatically enhanced cell killing mediated by DNA-damaging chemotherapy drugs. Single-cell analysis revealed that CCR5 governs PI3K / Akt, ribosome biogenesis, and cell survival signaling [Jiao-2018].
[0020] The role of CCR5 blockade of the CCL5-CCR5 pathway in tumor immune control has recently been demonstrated, providing new horizons for targeting this deadly disease [de Oliveira, 2017; Del Prete, 2017; Lanitis, 2017]. CCR5 immunohistochemistry of biopsies allows selectively selecting patients with CCR5 expression not only on the tumor but also on intratumoral immune cells in the tumor microenvironment.
[0021] Targeted therapy with one or more CCR5 binding agents, such as leronlimab (PRO140), may have the potential to increase overall response rates due to synergy in DNA cross-strand breaks with chemotherapy agents such as carboplatin and reduced DNA repair secondary to CCR5 binding by leronlimab (PRO140).
[0022] Glossary Before describing this disclosure in more detail, it may be helpful to its understanding to provide definitions of certain terms to be used herein. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Additional definitions are set forth throughout this disclosure.
[0023] Unless otherwise indicated, any concentration range, percentage range, ratio range, or integer range described herein should be understood to include any integer value within the described range, and where appropriate, fractions thereof (e.g., tenths and hundredths of integers).Also, unless otherwise indicated, any numerical range described herein for any physical characteristic, such as dose, should be understood to include any integer within the described range.Unless otherwise indicated, the term "about" used herein means ±20% of the indicated range, value, or structure.
[0024] As used herein, the terms "a" and "an" should be understood to refer to "one or more" of the components that they are counted. The use of alternatives (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives.
[0025] As used herein, the terms "comprise," "have," and "include" are used interchangeably and these terms and variations thereof are intended to be construed as open ended.
[0026] The term "consisting essentially of" limits the scope of a claim to the recited materials or steps or to those that do not materially affect the essential characteristics of the claimed invention. For example, a protein domain, region, or module (e.g., a binding domain, hinge region, linker module) or protein (which may have one or more domains, regions, or modules) "consists essentially of" a particular amino acid sequence when the amino acid sequence of the domain, region, or module, or protein, includes extensions, deletions, mutations, or any combination thereof (e.g., amino acids at the amino or carboxy termini or between domains), which in combination contribute to at most 20% (e.g., at most 15%, 10%, 8%, 6%, 5%, 4%, 3%, 2%, or 1%) of the length of the domain, region, or module, or protein, and do not substantially affect (i.e., do not reduce) the activity of the domain(s), region(s), module(s), or protein (e.g., the target binding affinity of a binding protein) by more than 50%, e.g., by more than 40%, 30%, 25%, 20%, 15%, 10%, 5%, or 1%).
[0027] As used herein, "chemokine" refers to a cytokine that can stimulate the movement of white blood cells. Depending on whether the two amino-terminal cysteine residues are immediately adjacent or separated by one amino acid, chemokines can be characterized as either cys-cys or cys-X-cys. It includes, but is not limited to, CCL5 (also known as RANTES), MIP-1α, MIP-1β, or SDF-1, or another chemokine with similar activity.
[0028] As used herein, "chemokine receptor" refers to a member of a homologous family of seven transmembrane cell surface proteins that bind chemokines.
[0029] As used herein, "CCR5" is a chemokine receptor that binds members of the CC family of chemokines, the amino acid sequence of which includes that provided in Genbank Accession No. 1705896 and associated polymorphic variants.
[0030] As used herein, "antibody" refers to an immunoglobulin molecule that contains two heavy chains and two light chains that recognize an antigen. Immunoglobulin molecules can be derived from any of the commonly known classes or isotypes, including, but not limited to, IgA, secretory IgA, IgG, and IgM. IgG subclasses are also well known to those skilled in the art, including, but not limited to, human IgG1, IgG2, IgG3, and IgG4. It includes, by way of example, both naturally occurring and non-naturally occurring antibodies. Specifically, "antibody" includes polyclonal and monoclonal antibodies, as well as monovalent and divalent fragments thereof. Furthermore, "antibody" includes chimeric antibodies, totally synthetic antibodies, single-chain antibodies, and fragments thereof. Optionally, the antibody can be labeled with a detectable marker. Detectable markers include, for example, radioactive or fluorescent markers. The antibody can be a human or non-human antibody. A non-human antibody can be humanized by recombinant methods to reduce its immunogenicity in humans. Methods for humanizing antibodies are known to those skilled in the art.
[0031] As used herein, "monoclonal antibody," also referred to as "mAb," is used to describe antibody molecules that are essentially identical in their primary sequence and display the same antigen specificity. Monoclonal antibodies may be produced by hybridoma, recombinant, transgenic, or other techniques known to those of skill in the art.
[0032] As used herein, "heavy chain" refers to the larger polypeptide of an antibody molecule consisting of one variable domain (VH) and three or four constant domains (CH1, CH2, CH3, and CH4) or fragments thereof.
[0033] As used herein, "light chain" refers to the smaller polypeptide of an antibody molecule consisting of one variable domain (VL) and one constant domain (CL) or fragments thereof.
[0034] As used herein, "binding fragment" or "antigen-binding fragment or portion" of an antibody refers to a fragment or portion of an intact antibody that has or retains the ability to bind to the antigen target molecule recognized by the intact antibody. Fragments include single-chain antibody fragments, including antigen-binding (Fab) fragments, F(ab')2 fragments, Fab' fragments, Fv fragments, recombinant IgG (rIgG) fragments, single-chain variable fragments (scFv) and single-domain antibody (e.g., sdAb, sdFv, nanobody) fragments. The term encompasses genetically engineered or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multispecifics such as bispecific antibodies, diabodies, triabodies, tetrabodies, tandem di-scFv, and tandem tri-scFv.
[0035] As used herein, "Fab" refers to a monovalent antigen-binding fragment of an immunoglobulin that consists of one light chain and part of a heavy chain, which can be obtained by brief papain digestion or by recombinant methods.
[0036] As used herein, "F(ab')2 fragment" refers to a bivalent antigen-binding fragment of an immunoglobulin that consists of both light chains and part of both heavy chains. It can be obtained by brief pepsin digestion or by recombinant methods.
[0037] As used herein, "CDR" or "complementarity determining region" refers to a highly variable sequence of amino acids in the variable domain of an antibody.
[0038] "Humanized" as used herein refers to an antibody in which some, most, or all of the amino acids outside the CDR regions are replaced by corresponding amino acids derived from a human immunoglobulin molecule. In one embodiment of a humanized form of an antibody, some, most, or all of the amino acids outside the CDR regions are replaced by amino acids from a human immunoglobulin molecule, while some, most, or all of the amino acids in one or more CDR regions are left unchanged. Small additions, deletions, insertions, substitutions, or modifications of amino acids are acceptable as long as they will not abolish the ability of the antibody to bind to a given antigen. Suitable human immunoglobulin molecules would include IgG1, IgG2, IgG3, IgG4, IgA, and IgM molecules. A "humanized" antibody would retain a similar antigen specificity as the original antibody, for example, the ability to bind to CCR5 in this disclosure.
[0039] Those skilled in the art will know how to make the humanized antibody of the present disclosure. Various publications, some of which are incorporated herein by reference, also describe how to make humanized antibodies. For example, the method described in US Pat. No. 4,816,567 involves the production of chimeric antibodies with the variable region of one antibody and the constant region of another antibody. US Pat. No. 5,225,539 describes another approach for the production of humanized antibodies. This patent describes the use of recombinant DNA technology to produce humanized antibodies. Humanized antibodies are antibodies in which the CDRs of the variable region of one immunoglobulin are replaced by CDRs from an immunoglobulin with different specificity, such that the antibody recognizes the desired target but is not recognized in a significant manner by the immune system of the human subject. Specifically, site-directed mutagenesis is used to graft the CDRs onto a framework.
[0040] Other approaches to humanizing antibodies are described in US Pat. Nos. 5,585,089 and 5,693,761 and WO 90 / 07861. These describe methods for producing humanized immunoglobulins. These have one or more CDRs and possibly additional amino acids from a donor immunoglobulin and a framework region from an acceptor human immunoglobulin. These patents describe methods for increasing the affinity of antibodies to a desired antigen. Some amino acids on the framework are selected to be the same as the amino acids at those positions on the donor rather than the acceptor. Specifically, these patents describe the preparation of humanized antibodies that bind to a receptor by combining the CDRs of a mouse monoclonal antibody with human immunoglobulin framework and constant regions. The human framework regions can be selected to maximize homology with the mouse sequence. Computer models can be used to identify amino acids on the CDRs or framework regions that are likely to interact with a particular antigen, and then mouse amino acids can be used at those positions to create a humanized antibody.
[0041] The above US Pat. Nos. 5,585,089 and 5,693,761 and WO 90 / 07861 also propose four possible criteria that can be used to design a humanized antibody. The first proposal was to use for the acceptor a framework from a particular human immunoglobulin that is unconventionally homologous to the donor immunoglobulin to be humanized, or to use a consensus framework from many human antibodies. The second proposal was that if an amino acid on the framework of a human immunoglobulin is unconventional and the donor amino acid at that position is typical for human sequences, the donor amino acid rather than the acceptor amino acid can be selected. The third proposal was that in positions immediately adjacent to the three CDRs on the humanized immunoglobulin chain, the donor amino acid rather than the acceptor amino acid can be selected. The fourth proposal was to use a donor amino acid residue in a framework position where the amino acid is predicted to have a side chain atom within 3A of the CDR in a three-dimensional model of the antibody and is predicted to be able to interact with the CDR. The above methods are merely illustrative of some of the methods that one skilled in the art may employ to make humanized antibodies. The binding affinity and / or specificity of humanized antibodies may be increased using directed evolution methods as described in Wu et al., J. MOL. BIOL., 284: 151 (1999) and US Pat. Nos. 6,165,793; 6,365,408; and 6,413,774.
[0042] The variable region of the humanized antibody can be linked to at least a portion of the immunoglobulin constant region of a human immunoglobulin. In one embodiment, the humanized antibody contains both light and heavy chain constant regions. The heavy chain constant region usually includes CH1, hinge, CH2, CH3, and optionally CH4 regions. In one embodiment, the constant region of the humanized antibody is of human IgG4 isotype.
[0043] The antibody or binding fragment disclosed herein can be either labeled or unlabeled. Unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with humanized antibodies, such as antibodies specific for human immunoglobulin constant regions. Alternatively, antibodies can be directly labeled. A wide variety of labels can be employed, such as radionuclides, fluorescent dyes, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (especially haptens), and the like. Numerous types of immunoassays for detecting CCR5-expressing cells or CCR5 modulation on cells capable of expressing CCR5 are available and are well known to those skilled in the art.
[0044] The present disclosure also provides antibody or antibody fragment-polymer conjugates with effective size or molecular weight or incorporate other half-life extension technologies that confer increased serum half-life, increased mean residence time in circulation (MRT), and / or decreased serum clearance rate compared to underivatized antibody fragments. Antibody fragment-polymer conjugates can be made by derivatizing the desired antibody fragment with an inert polymer. It will be understood that any inert polymer that provides the conjugate with the desired apparent size or has a selected actual molecular weight is suitable for use in constructing the antibody fragment-polymer conjugates of the present disclosure.
[0045] Many inert polymers are suitable for pharmaceutical use. See, for example, Davis et al., Biomedical Polymers: Polymeric Materials and Pharmaceuticals for Biomedical Use, pp. 441-451 (1980). Nonproteinaceous polymers are used in the antibody or antibody fragment-polymer conjugates disclosed herein. Nonproteinaceous polymers are typically hydrophilic synthetic polymers, i.e., polymers not otherwise found in nature. However, naturally occurring and recombinant or in vitro produced polymers are also useful, as are polymers isolated from native sources. Hydrophilic polyvinyl polymers, such as polyvinyl alcohol and polyvinylpyrrolidone, fall within the scope of the present disclosure. Polyalkylene ethers, such as polyethylene glycol (PEG); polyoxyalkylenes, such as polyoxyethylene, polyoxypropylene, and block copolymers of polyoxyethylene and polyoxypropylene (Pluronics); polymethacrylates; carbomers; the sugar monomers D-mannose, D and L-galactose, fucose, fructose, D-xylose, L-arabinose, D-glucuronic acid, sialic acid, D-galacturonic acid, D-mannuronic acid (e.g. poly Particularly useful are branched or unbranched polysaccharides including polysaccharides such as homopolysaccharides and heteropolysaccharides, including polysaccharide subunits of polysaccharides such as lactose, amylopectin, starch, hydroxyethyl starch, amylose, dextran sulfate, dextran, dextrin, glycogen, or acid mucopolysaccharides such as hyaluronic acid, polymers of sugar alcohols such as polysorbitol and polymannitol, heparin, or heparon. Prior to crosslinking, the polymer is preferably, but need not be, water-soluble, but the final conjugate must be water-soluble. Preferably, the conjugate exhibits a water solubility of at least about 0.01 mg / ml, more preferably at least about 0.1 mg / ml, and even more preferably at least about 1 mg / ml.In one embodiment, the polymer should not be highly immunogenic in the conjugated form, nor should it possess a viscosity that is incompatible with intravenous infusion or injection if the conjugate is intended to be administered by such routes.
[0046] In one embodiment, the polymer contains only a single group that is reactive. This helps to avoid cross-linking of protein molecules. However, it is within the scope of this disclosure to optimize reaction conditions to reduce cross-linking, or to purify the reaction products by gel filtration or ion exchange chromatography to recover substantially homogeneous derivatives. In other embodiments, the polymer contains two or more reactive groups for the purpose of linking multiple antibody fragments to the polymer backbone.
[0047] Gel filtration or ion exchange chromatography may be used to recover the desired derivative in substantially homogeneous form.
[0048] The molecular weight of the polymer may range up to about 500,000 D, and is preferably at least about 20,000 D, or at least about 30,000 D, or at least about 40,000 D. The molecular weight chosen may depend on the effective size of the conjugate to be achieved, the nature of the polymer (e.g., linear or branched structure, etc.), and the degree of derivitization, i.e., the number of polymer molecules per antibody fragment, as well as the site(s) of polymer attachment on the antibody fragment.
[0049] The polymer may be covalently linked to the antibody fragment via a polyfunctional crosslinker that reacts with the polymer and one or more amino acid residues of the antibody fragment to be linked, however, it is also within the scope of this disclosure to crosslink the polymer directly by reacting a derivatized polymer with the antibody fragment or vice versa.
[0050] Covalent cross-linking sites on antibody fragments include the N-terminal amino group and the epsilon amino group found on lysine residues, as well as other amino, imino, carboxyl, sulfhydryl, hydroxyl, or other hydrophilic groups. Polymers can be covalently attached directly to antibody fragments without the use of polyfunctional (usually bifunctional) cross-linking agents, as described in US Pat. No. 6,458,355.
[0051] The degree of substitution of such polymers will vary depending on the number of reactive sites on the antibody fragment, the molecular weight, hydrophilicity, and other characteristics of the polymer, and the particular antibody fragment derivitization site chosen. Generally, the conjugate contains from 1 to about 10 polymer molecules, although greater numbers of polymer molecules attached to the antibody fragment of the present disclosure are also contemplated. The desired amount of derivitization is easily achieved by using an experimental matrix in which time, temperature, and other reaction conditions are varied to change the degree of substitution. Following this, the level of polymer substitution of the conjugate is determined by size exclusion chromatography or other means known in the art.
[0052] Functionalized PEG polymers for modifying the antibody fragments of the present disclosure are available from Shearwater Polymers, Inc. (Huntsville, Ala.) Such commercially available PEG derivatives include, but are not limited to, amino-PEG, PEG amino acid ester, PEG-hydrazide, PEG-thiol, PEG-succinate, carboxymethylated PEG, PEG-propionic acid, PEG amino acid, PEG succinimidyl succinate, PEG succinimidyl propionate, succinimidyl ester of carboxymethylated PEG, succinimidyl carbonate of PEG, succinimidyl ester of amino acid PEG, PEG-oxycarbonylimidazole, PEG-nitrophenyl carbonate, PEG tresylate, PEG-glycidyl ether, PEG-aldehyde, PEG-vinyl sulfone, PEG-maleimide, PEG-orthopyridyl-disulfide, heterofunctional PEG, PEG vinyl derivatives, PEG silane, and PEG phosphoride. The reaction conditions for coupling these PEG derivatives will vary depending on the protein, the desired degree of PEGylation, and the PEG derivative utilized. Several factors go into the selection of a PEG derivative, including: the desired attachment point of the derivative (e.g., lysine or cysteine R group), hydrolytic stability, and reactivity, linkage stability, toxicity, and antigenicity, suitability for analysis, etc. Specific instructions for use of any particular derivative are available from the manufacturer. These conjugates can be separated from unreacted starting material by gel filtration or ion exchange HPLC.
[0053] As used herein, an "anti-chemokine receptor antibody" refers to an antibody that recognizes and binds to an epitope on a chemokine receptor. As used herein, an "anti-CCR5 antibody" refers to a monoclonal antibody that recognizes and binds to an epitope on the CCR5 chemokine receptor.
[0054] As used herein, "epitope" refers to a portion of a molecule or molecules that forms a surface for binding an antibody or other compound. Epitopes can include a specific surface of consecutive or non-consecutive amino acids, carbohydrates, or other non-peptidyl moieties, or oligomers.
[0055] As used herein, "polypeptide" means two or more amino acids linked by peptide bonds.
[0056] A "nucleic acid molecule" or "polynucleotide" can be in the form of RNA or DNA, including cDNA, genomic DNA, and synthetic DNA. A nucleic acid molecule can be double-stranded or single-stranded. If single-stranded, it can be a coding strand or a non-coding (antisense) strand. A coding molecule can have a coding sequence identical to a coding sequence known in the art, or a different coding sequence that can code for the same polypeptide as a result of redundancy or degeneracy of the genetic code or by splicing.
[0057] An "analog" of an antibody or binding fragment includes a molecule that differs from the antibody or binding fragment by conservative amino acid substitutions. For the purpose of classifying amino acid substitutions as conservative or non-conservative, amino acids can be grouped as follows: Group I (hydrophobic side chains): met, ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gin, his, lys, arg; Group V (residues that affect chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids of the same class. Non-conservative substitutions constitute exchanging a member of one of these classes for a member of another.
[0058] Due to the degeneracy of the genetic code, a variety of nucleic acid sequences code for the proteins or polypeptides disclosed herein. For example, a homologous nucleic acid molecule may comprise a nucleotide sequence that is at least about 90% identical to a reference nucleotide sequence. More preferably, the nucleotide sequence is at least about 95% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to a reference nucleotide sequence. Homology can be calculated using a variety of publicly available software tools well known to those skilled in the art. Exemplary tools include the BLAST system available from the website of the National Center for Biotechnology Information (NCBI) of the National Institutes of Health.
[0059] One method of identifying highly homologous nucleotide sequences is by nucleic acid hybridization.Hence, homologous nucleic acid molecules hybridize under high stringency conditions.Identification of related sequences can also be achieved using polymerase chain reaction (PCR) and other amplification techniques suitable for cloning related nucleic acid sequences.Preferably, PCR primers are selected to amplify the portion of the nucleic acid sequence of interest, such as CDR.
[0060] The term "high stringency conditions" used herein refers to parameters that are well known in the art.Nucleic acid hybridization parameters can be found in references that summarize such methods, such as MOLECULAR CLONING: A LABORATORY MANUAL, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) or CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, FM Ausubel, et al., eds., John Wiley & Sons, Inc., New York. One example of high stringency conditions is hybridization in hybridization buffer (3.5xSSC, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin, 2.5mM NaH2PO4 (pH7), 0.5% SDS, 2mM EDTA) at 65%. SSC is 0.15M sodium chloride / 0.015M sodium citrate pH7; SDS is sodium dodecyl sulfate; EDTA is ethylenediaminetetraacetic acid. After hybridization, the membrane to which the nucleic acid has been transferred is washed, for example, with 2xSSC at room temperature and then with 0.1-0.5xSSC / 0.1xSDS at temperatures up to 68%.
[0061] As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid. A vector can be, for example, a plasmid, cosmid, virus, or phage. An "expression vector" is a vector that, when present in the appropriate environment, can direct the expression of a protein encoded by one or more genes carried by the vector.
[0062] A nucleic acid sequence can be expressed by a host after the sequence is operably linked (i.e., positioned so as to ensure its function) to an expression control sequence. These expression vectors are typically replicable by the host organism either as episomes or as an integral part of the host chromosomal DNA. To enable detection of cells transformed with the desired DNA sequence, the expression vector will usually contain a selection marker, such as tetracycline or neomycin. See, e.g., US Pat. No. 4,704,362, which is incorporated herein by reference.
[0063] Once expressed, whole antibodies of the present disclosure, their dimers, individual light and heavy chains, or other immunoglobulin forms or binding fragments can be purified according to standard procedures in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis, and the like. See generally, R. Scopes, PROTEIN PURIFICATION, Springer-Verlag, New York (1982). For pharmaceutical uses, substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, with 98 to 99% or more homogeneity being most preferred. Once purified, partially or to homogeneity as desired, the polypeptides can then be used in developing and performing therapeutic (including in vitro) or assay procedures, immunofluorescence staining, and the like. See generally, IMMUNOLOGICAL METHODS, Vols. I and II, Lefkovits and Pernis, eds., Academic Press, New York, NY (1979 and 1981).
[0064] As used herein, "inhibit" means that the amount is reduced in the presence of the composition compared to the amount that would occur in the absence of the composition.
[0065] As used herein, the term "competitive inhibitor" refers to a molecule that competes with a reference molecule for binding to a target, thereby slowing down, inhibiting, reducing, diminishing or blocking the effect of the reference molecule on the target.For example, PRO140 is a competitive inhibitor of CCL5 binding to CCR5 receptor.
[0066] "Agonist activity," as used in this disclosure, refers to the binding by a molecule to a target such that the binding activates the target to produce a response.
[0067] As used herein, "CCL5 agonist activity" refers to activity consistent with activation by CCL5.
[0068] "Antagonist activity," as used in this disclosure, refers to binding by a molecule to a target where the binding does not activate the target to produce a response and where the binding blocks the action of one or more agonist molecules.
[0069] "Subject" as used herein means any animal or artificially modified animal that can have cancer.Artificially modified animals include, but are not limited to, SCID mice with human immune system.Animals include, but are not limited to, mice, rats, dogs, guinea pigs, ferrets, rabbits, and primates.In a preferred embodiment, the subject is a human.
[0070] As used herein, "treating" refers to slowing, stopping, or reversing the progression of a given disease or disorder. In preferred embodiments, "treating" refers to reversing the progression of a disease or disorder. In some embodiments, treating includes reversing the progression of a disease or disorder to the point of eliminating the disease or disorder.
[0071] As used herein, "prevent" refers to prevent a disease or disorder from occurring; delay the progression of a disease or disorder; or reduce the pathology or symptomology of a disease or disorder.For example, preventing cancer includes preventing the development of tumors, slowing down the growth of tumors, and delaying the development of tumors.
[0072] As used herein, "administering" can be accomplished or performed using any of the methods known to those of skill in the art, which can include oral, intravenous, intramuscular, or subcutaneous means.
[0073] As used herein, "effective dose" refers to an amount in sufficient quantity to either treat a subject or prevent a subject from developing cancer. One skilled in the art can perform simple titration experiments to determine what amount is required to treat a subject.
[0074] CCR5-binding drugs In one aspect, the disclosure relates to the use of CCR5 binding agents, in addition to DNA damaging agents, that target the CCR5 receptor and act as competitive inhibitors for the CCR5 cell receptor without providing CCL5 agonist activity.
[0075] In one embodiment, the present disclosure provides the use of PRO140 antibody or binding fragment thereof to treat or prevent cancer. PRO140 is a humanized monoclonal antibody described in US.Pat.No.7,122,185 and 8,821,877, which are incorporated herein by reference in their entirety. PRO140 is a humanized version of PA14, a murine mAh directed against CD4+CCR5+ cells. Olson et al., Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp 120 Binding and CC-Chemokine Activity of Monoclonal Antibodies to CCR5, J. VIROL., 73: 4145-4155. (1999). In vitro and in the hu-PBL-SCID mouse model of HIV-1 infection, PRO140 binds to CCR5 expressed on the surface of cells and potently inhibits HIV-1 entry and replication at concentrations that do not affect CCR5 chemokine receptor activity. Olson et al., Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp 120 Binding and CC-Chemokine Activity of Monoclonal Antibodies to CCR5, J. VIROL., 73: 4145-4155. (1999); Trkola et al., Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140, J. VIROL., 75: 579-588 (2001).
[0076] Nucleic acids encoding the heavy and light chains of the humanized PRO140 antibody have been deposited with the ATCC. Specifically, plasmids designated pVKHuPRO140, pVg4-HuPRO140(mut B+D+I), and pVg4-HuPRO140 HG2, respectively, were deposited with the ATCC, Manassas, Va., USA 20108, on Feb. 22, 2002, under ATCC Accession Nos. PTA4097, PTA4099, and PTA4098, respectively, in accordance with and in fulfillment of the requirements of the Budapest Treaty. The American Type Culture Collection (ATCC) is now located at 10801 University Boulevard, Manassas, Va. 20110-2209.
[0077] In one embodiment, the methods disclosed herein include administering a humanized antibody designated PRO140 or an antibody that competes with PRO140 for binding to the CCR5 receptor, where PRO140 comprises (i) two light chains, each of which comprises the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC deposit designation PTA-4097), and (ii) two heavy chains, each of which comprises the expression product of either a plasmid designated pVg4:HuPRO140 HG2-VH (ATCC deposit designation PTA-4098) or a plasmid designated pVg4:HuPRO140(mut B+D+I)-VH (ATCC deposit designation PTA-4099). In a further embodiment, PRO140 is a humanized or human antibody that binds to the same epitope as antibody PRO140 binds. In another embodiment, the monoclonal antibody is a humanized antibody designated PRO140.
[0078] In a further aspect, the disclosure relates to the use of a human antibody, or binding fragment thereof, designated CCR5mAb004, which is a fully human mAb generated using Abgenix XenoMouse® technology, that specifically recognizes and binds CCR5. Roschke et al., Characterization of a Panel of Novel Human Monoclonal Antibodies That Specifically Antagonize CCR5 and Block HIV Entry, 44th Annual Interscience CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Washington, D C., Oct. 30-Nov. 2, 2004 (2004);HGS Press Release, Human Genome Sciences Characterizes Panel of Novel Human See Monoclonal Antibodies That Specifically Antagonize the CCR5 Receptor and Block HIV-1 Entry, Nov. 2, 2004 (2004);HGS Press Release, Human Genome Sciences Begins Dosing of Patients in a Phase 1 Clinical Trial of CCR5 mAh in Patients Infected With HIV-1, Mar. 30, 2005 (2005).
[0079] In one aspect, the present disclosure relates to the use of monoclonal antibody PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610), a binding fragment thereof, or an antibody that competes with monoclonal antibody PA14 in binding to the CCR5 receptor, in treating or preventing cancer.
[0080] In one embodiment, the CCR5 binding agent may include a small molecule such as, for example, vicriviroc, UK-427,857, maraviroc, GW873140, TAK-652, Takeda AMD070, or the like.
[0081] In one embodiment of the methods described herein, the antibody or binding fragment thereof comprises a light chain of the antibody. In another embodiment, the antibody or binding fragment thereof comprises a heavy chain of the antibody. In a further embodiment, the antibody or binding fragment thereof comprises a Fab portion of the antibody. In a still further embodiment, the antibody or binding fragment thereof comprises a F(ab')2 portion of the antibody. In an additional embodiment, the antibody or binding fragment thereof comprises an Fd portion of the antibody. In another embodiment, the antibody or binding fragment thereof comprises an Fv portion of the antibody. In a further embodiment, the antibody or binding fragment thereof comprises a variable domain of the antibody. In yet a further embodiment, the antibody or binding fragment thereof comprises one or more CDR domains of the antibody. In yet another embodiment, the antibody or binding fragment thereof comprises six CDR domains of the antibody.
[0082] The CC-chemokine receptor CCR5 is the largest coreceptor for macrophage-tropic (R5) strains and plays a crucial role in sexual transmission of HIV-1. It has been demonstrated that tyrosine and negatively charged residues on the amino-terminal domain (Nt) of CCR5 are essential for gp120 binding to the coreceptor as well as for HIV-1 fusion and entry. Residues on the extracellular loops (ECLs) 1–3 of CCR5 were not essential for coreceptor function, but the CCR5 interdomain configuration had to be maintained for optimal viral fusion and entry (24). This led to the conclusion that either gp120 forms interactions with a diffuse surface on the ECL or the Nt is maintained in a functional conformation by binding with residues on the ECL. Studies with chimeric coreceptors and anti-CCR5 monoclonal antibodies also demonstrated the importance of the extracellular loops for viral entry.
[0083] The G protein-coupled receptor CCR5 is normally expressed on a subset of T cells and serves as a coreceptor for HIV infection. CCR5 is a prerequisite fusion coreceptor for HIV-1 primary isolates. PRO140 is an anti-CCR5 monoclonal antibody that potently inhibits HIV-1 entry and replication in vitro at concentrations that do not affect the chemokine receptor activity of CCR5. During malignant transformation, CCR5 expression is known to increase in several cancers (breast cancer (BCa), prostate cancer, colon cancer, melanoma). Cancer clinical trials targeting CCR5 with small molecule inhibitors began accruing in late 2018. CCR5 is expressed in >50% of human BCa, primarily in triple-negative BCa. Its expression in human BCa correlates with poor outcome, and in mice, CCR5 expression correlates with poor outcome. + BCa epithelial cells have cancer stem cell characteristics, form tumor-like masses, and initiate tumors with >60-fold greater efficiency. Reintroduction of CCR5 expression into CCR5-negative BCa cells promotes tumor metastasis and induces DNA repair gene expression and activity. The CCR5 inhibitor leronlimab has been used to treat >660 patients with HIV and included meeting its primary endpoint of a phase III study with no reported significant adverse events.
[0084] Here we report that leronlimab bound to CCR5 expressed in human breast cancer cell lines with 98% efficiency. Leronlimab inhibited CCL5-induced Ca +2It abolished flux and blocked 3D Matrigel invasion of MDA-MB-231 cells. The inflammatory chemokine CCL5 (CC chemokine ligand 5), also known as regulated by activation, expressed and secreted by normal T cells (RANTES), plays a key role in these immunological mechanisms. CCL5 acts as a key regulator of T cell migration to sites of inflammation, directing T cell migration to sites of injury or infection. CCL5 also regulates T cell differentiation. Many biological effects of chemokines are mediated by their interaction with chemokine receptors on the cell surface. In this disclosure, the most relevant known receptor for CCL5 is the CCR5 receptor; however, CCR1 and CCR3 are also known CCL5 receptors, and CCR4 and CD44 are co-receptors.
[0085] The CCR5 receptor is a CC chemokine G-coupled protein receptor and is expressed on lymphocytes (e.g. NK cells, B cells), monocytes, macrophages, dendritic cells, a subset of T cells, etc. The CCR5 receptor penetrates the plasma membrane of cells seven times in a serpentine manner. The extracellular portion represents a possible target for antibodies targeting CCR5 and includes an amino-terminal domain (Nt) and three extracellular loops (ECL1, ECL2, and ECL3). The extracellular portion of CCR5 contains just 90 amino acids distributed over four domains. The largest of these domains are in the Nt and ECL2, each with approximately 30 amino acids.
[0086] Formation of the complex of the CCL5 ligand and the CCR5 receptor causes a conformational change in the receptor that activates G protein subunits and induces signal transduction leading to altered levels of cyclic AMP (cAMP), inositol triphosphate, intracellular calcium, and tyrosine kinase activation. These signaling events lead to cell polarization and translocation of the transcription factor NF-kB, which results in increased phagocytic capacity, cell survival, and transcription of pro-inflammatory genes. Once G protein-dependent signaling has occurred, the CCL5 / CCR5 receptor complex is internalized by endocytosis.
[0087] The complete complex structure of CCL5 in complex with CCR5 has been derived computationally. It has been reported that residues 1-15 of CCL5 are inserted into the CCR5 binding pocket; the N-terminal domain 1-6 of CCL5 is buried in the transmembrane region of CCR5; and residues 7-15 of CCL5 are predominantly enveloped by the N-terminal domain and extracellular loops of CCR5. CCL5 residues Ala16 and Arg17 and additional residues in residues 24-50 interact with the upper N-terminal domain and extracellular loop interface of CCR5. It has also been reported that the integrity of the amino terminus of CCL5 is critical for receptor binding and cell activation. It has also been reported that CCL5 and HIV-1 interact primarily with almost identical CCR5 residues and share the same chemokine receptor binding pocket.
[0088] CCR5 signaling has antitumor effects, acts as a costimulatory molecule for T cell activation, and increases T cell chemotaxis to the tumor microenvironment. CCL5 / CCR5 axis signaling can be preferentially activated in certain types of cancer, such as breast and prostate cancer, and such signaling facilitates disease progression. Cancer cells can overexpress CCL5, CCR5, or both, likely contributing to their growth and proliferation through the effect of CCR5 signaling on the mechanistic target of rapamycin (mTOR). In addition, some immunosuppressive immune cells, including regulatory T cells (Tregs) and myeloid-derived immunosuppressive cells (MDSCs), express CCR5, suggesting another pathway by which CCR5 signaling may contribute to tumor growth. Cancer cells in the tumor microenvironment express CD4 + and CD8 + CCL5 production by T cells can be harnessed to lead to increased tumor growth and tumor cell progression.
[0089] PRO140 (leronlimab) is known to bind to the CCR5 receptor and shares some binding commonalities with CCL5. Leronlimab binds to CCR5 receptor amino acid residues on EL2 alone or in combination with Nt residues. This binding of anti-CCR5 monoclonal antibodies to the CCR5 receptor binding site is distinct from that of small molecule CCR5 binding agents.
[0090] It has been previously shown that monoclonal antibody PRO140 has no effect on cAMP levels when added alone to CD4+ T cells, but when administered together with CCL5, it attenuates the effect of CCL5 on cAMP levels. Similarly, PRO140 alone does not affect the chemotaxis of CHO-K1 cells, but when administered together with CCL5, PRO140 reduces the chemotaxis induced by CCL5. PRO140 has no agonistic activity for CCR5, but acts as a competitive inhibitor of CCL5 for binding to CCR5.
[0091] Leronlimab blocks human breast cancer xenograft metastasis in mice. Leronlimab also enhanced cell killing by agents that induce DNA damage, including doxorubicin.
[0092] Leronlimab was found to bind to CCR5 on BCa cells, block breast cancer cell invasion and tumor metastasis, and enhance cell killing by chemotherapy that induces DNA damage. Because CCR5 enhances DNA repair and is selectively expressed on cancerous but not normal breast epithelial cells, Leronlimab may enhance the tumor-specific activity of DNA damage response (DDR)-based treatments and allow for reduced chemotherapy and radiation doses.
[0093] The studies described herein evaluate the binding and functional interactions of a humanized monoclonal antibody against CCR5 (leronlimab) with human breast cancer cell lines.
[0094] How to use In one aspect, the present disclosure provides a method for treating or preventing cancer, comprising administering a competitive inhibitor to a subject in need thereof against CCR5 cell receptor. In certain embodiments, a method for preventing cancer is provided.
[0095] In one embodiment, the present disclosure provides a method for preventing cancer, comprising administering to a subject in need thereof a competitive inhibitor for CCR5 cell receptor that does not have CCL5 agonist activity by itself, the competitive inhibitor binds to the ECL2 loop of CCR5 cell receptor. In a further embodiment, the competitive inhibitor competes with CCL5 for binding to CCR5 cell receptor. In a further embodiment, the competitive inhibitor comprises monoclonal antibody PRO140 or a binding fragment thereof. In a further embodiment, the competitive inhibitor competes with monoclonal antibody PRO140 or a binding fragment thereof for binding to.
[0096] In one embodiment, the disclosure provides a method of preventing cancer comprising administering to a subject in need thereof: (a) a PRO140 antibody or binding fragment thereof; (b) a nucleic acid encoding a PRO140 antibody or binding fragment thereof; (c) a vector comprising a nucleic acid encoding a PRO140 antibody or binding fragment thereof; or (d) a host cell comprising (i) a PRO140 antibody or binding fragment thereof, (ii) a nucleic acid encoding a PRO140 antibody or binding fragment thereof, or (iii) a vector comprising a nucleic acid encoding a PRO140 antibody or binding fragment thereof. In the foregoing embodiments, the PRO140 antibody or binding fragment thereof may comprise, for example, a PRO140 monoclonal antibody or scFv.
[0097] In one aspect, the disclosure provides a method of preventing cancer, comprising administering to a subject in need thereof a PRO140 antibody or binding fragment thereof.
[0098] In one embodiment, the competitive inhibitor for the CCR5 cell receptor, such as PRO140, is administered with a pharma- ceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those skilled in the art. Such pharma- ceutically acceptable carriers can include, but are not limited to, aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, saline, and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, Ringer's lactate, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as antimicrobial agents, antioxidants, chelating agents, inert gases, and the like.
[0099] The dose of the composition of the present invention will vary depending on the subject and the specific administration route used. The dose can range from 0.1 to 100,000 μg / kg. Depending on the composition, the dose can be delivered continuously, for example by a continuous pump, or at regular intervals, for example at one or more separate times. The desired time interval between multiple doses of a particular composition can be determined by one of ordinary skill in the art without undue experimentation.
[0100] In one embodiment of the method, the antibody or binding fragment thereof is administered to the subject multiple times, with each administration delivering 0.01 mg / kg to 50 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers 0.05 mg / kg to 25 mg / kg of antibody or binding fragment thereof to the subject. In a further embodiment, each administration delivers 0.1 mg / kg to 10 mg / kg of antibody or binding fragment thereof to the subject. In yet a further embodiment, each administration delivers 0.5 mg / kg to 5 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers 1 mg / kg to 3 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers about 2 mg / kg of antibody or binding fragment thereof to the subject.
[0101] In one embodiment, the antibody or binding fragment thereof is administered multiple times, the first administration being spaced apart from the subsequent administration by an interval of less than one week. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of at least one week. In a further embodiment, the first administration is spaced apart from the subsequent administration by an interval of one week. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of two to four weeks. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of two weeks. In a further embodiment, the first administration is spaced apart from the subsequent administration by an interval of four weeks. In yet another embodiment, the antibody or binding fragment thereof is administered multiple times, the first administration being spaced apart from the subsequent administration by an interval of at least one month.
[0102] In a further aspect, the antibody or binding fragment thereof is administered to the subject by intravenous infusion. In another aspect, the antibody or binding fragment thereof is administered to the subject by subcutaneous injection. In another aspect, the antibody or binding fragment thereof is administered to the subject by intramuscular injection.
[0103] In some embodiments, PRO140 is administered in a weekly dose of 350 mg to 1400 mg, or about 525 mg, or about 700 mg, or about 1050 mg. In some embodiments, PRO140 is administered in a twice weekly dose of 350 mg to 1400 mg, or about 525 mg, or about 700 mg, or about 1050 mg.
[0104] In some embodiments, PRO140 is administered in a formulation comprising concentrated PRO140 in an amount greater than about 100 mg / mL and less than about 200 mg / mL; a tonicifier consisting essentially of a histidine and glycine buffer and a sodium salt, wherein the buffer is present in an amount of about 10 mM to about 25 mM and is present in a total amount of about 110 mM to about 120 mM; and a surfactant, wherein the formulation is hypotonic and has a total salt concentration of less than 100 mM.
[0105] In some embodiments, PRO140 is administered in a formulation comprising concentrated PRO140 in an amount greater than about 100 mg / mL and less than about 200 mg / mL; a sodium salt in an amount greater than about 90 mM and less than about 100 mM; a histidine and glycine buffer in an amount greater than about 5 mM and less than about 25 mM; a surfactant in an amount greater than about 0.001% w / v and less than about 0.2% w / v; and optionally a stabilizer or non-salt tonicifier in an amount of about 0.05% w / v to about 1.8% w / v, wherein the formulation has an osmolality of about 250 to about 280 mOsm and has a total salt concentration of less than 100 mM.
[0106] In some embodiments, PRO140 is administered as a low viscosity, hypotonic formulation comprising: (a) concentrated PRO140 in an amount of greater than about 100 mg / mL and less than about 200 mg / mL; (b) a sodium salt in an amount selected from about 90 mM or about 95 mM; (c) a histidine and glycine buffer in an amount of about 20 mM; (d) a surfactant in an amount of 0.005% to 0.2% w / v; and optionally (e) a stabilizer or non-salt tonicifier in an amount sufficient to provide an osmolality of the formulation of about 260-280 mOs / kg, wherein the formulation has a total salt concentration of less than 100 mM.
[0107] In some embodiments, PRO140 is administered as a low viscosity, hypotonic formulation comprising: (a) concentrated PRO140 in an amount of greater than about 100 mg / mL and less than about 200 mg / mL; (b) a salt in an amount selected from about 90 mM or about 95 mM, where the salt is selected from sodium chloride, sodium gluconate, or sodium lactate; (c) a histidine and glycine buffer in an amount of about 20 mM; (d) a surfactant in an amount of about 0.005% to about 0.2% w / v, where the surfactant is a polysorbate, poloxamer, or pluronic; and (e) a stabilizer or non-salt tonicifier present in an amount sufficient to provide an osmolality of the formulation of about 230 mOs / kg to about 280 mOs / kg, where the stabilizer or non-salt tonicifier is selected from a sugar alcohol, a monosaccharide, a disaccharide, or a combination thereof; and the formulation has a total salt concentration of less than 100 mM.
[0108] In some embodiments, PRO140 is administered in a composition comprising PRO140 in an amount greater than about 100 mg / mL and less than about 200 mg / mL, a tonicifier comprising a sodium salt present in a concentration greater than about 90 mM and a histidine and glycine buffer present in a total amount of 110 mM to 120 mM, and a surfactant present in an amount of about 0.001% to about 0.2% w / v, wherein the composition has an osmolality of about 230 to about 290 mOs / kg and a total salt concentration of less than 100 mM.
[0109] In some embodiments, PRO140 is provided as an article of manufacture comprising a container and a formulation comprising PRO140 at a concentration of greater than 100 mg / mL and less than 200 mg / mL, a sodium salt present in a concentration of greater than about 90 mM and a tonicifier of histidine and glycine buffer present in a total amount of about 110 mM to about 120 mM, a surfactant in an amount of about 0.005% to about 0.2%, and instructions for use, wherein the formulation has a total salt concentration of less than 100 mM.
[0110] In some embodiments, PRO140 will be administered in a 700 mg dose (175 mg / mL) of Leronlimab (PRO140) delivered as two injections of 2 mL each, administered subcutaneously on either side of the abdomen. Each vial of Leronlimab (PRO140) product may contain ~1.4 mL antibody at a concentration of 175 mg / mL.
[0111] In the embodiments described herein, therapeutic agents that are not CCR5-binding agents may be administered in conventional doses and using conventional methods.
[0112] In another embodiment, a therapeutic agent that is not a CCR5 binding agent may be administered at a lower dose due to a synergistic effect achieved with administration of the CCR5 binding agent.
[0113] CCR5 binding agents such as leronlimab can be administered together with non-CCR5 binding agents simultaneously or in sequential order. Regardless of the specific dosing regimen or order of introduction of the therapeutically effective agents, the administration together can be effectively achieved in which the subject experiences the therapeutic effect of each of the CCR5 binding agent and the non-CCR5 binding agent.
[0114] In any of the foregoing embodiments, the cancer may be, for example, breast cancer, prostate cancer, colon cancer, melanoma, gastric cancer, ovarian cancer, lung (non-small cell) cancer, pancreatic cancer, sarcoma, or blood cell cancer. In certain embodiments, the cancer is breast cancer. In certain embodiments, the cancer is metastatic breast cancer.
[0115] Methods for Treating Metastatic Breast Cancer In one aspect, the disclosure provides a method of treating or preventing metastatic breast cancer, comprising administering to a subject in need thereof a CCR5-binding agent in combination with another therapeutic agent.
[0116] In certain embodiments, the methods disclosed herein include administering leronlimab in combination with a DNA damaging agent, such as doxorubicin or carboplatin.
[0117] In one embodiment, a competitive inhibitor for the CCR5 cell receptor, e.g., PRO140, is administered in combination with one or more DNA damaging agents, e.g., chemotherapy, including: alkylating agents, e.g., thiotepa and cyclosphosphamide; alkyl sulfonates, e.g., busulfan, improsulfan, and piposulfan; aziridines, e.g., benzodopa, carboquone, metholedopa, and uredopa; altretamine, triethylenemelamine, triethylenephosphoramide, triethylenediamine ... ethyleneimines and methylamelamines, including triethylenethiophosphaoramide, and trimethylolomelamine; nitrogen mustards, such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembitine, phenesterine, prednisone; nitrosureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics, such as aclacinomycin, actinomycin, anthramycin, azaserine, bleomycin, cactinomycin, calicheamicin, carabicin, caminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine , doxorubicin, epirubicin, esorubicin, idarubicin, marcelomycin, mitomycin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfilomycin, puromycin, keramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, and trimetrexate;Purine analogues, such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogues, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, and 5-FU; androgens, such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, and testolactone; antiadrenal drugs, such as aminoglutethimide, mitotane, and trilostane; folic acid supplements, such as folinic acid acid);aceglatone;aldophosphamide glycosides;aminolevulinic acid;amsacrine;bestrabucil;bisantrene;edatrexate;defofamine;demecolcine;diazicon;elformitine;elliptinium acetate;ethoglucide;gallium nitrate;hydroxyurea;lentinan;lonidamine;mitoguazone;mitoxantrone;mopidamol;nitracrine;pentostatin;phenamet;pirarubicin;podophyllic acid;2-ethyline hydrazide; procarbazine; PSK™; razoxane; schizofiran; spirogermanium; tenuazonic acid; triazicon; 2,2',2''-trichlorotriethylamine; urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, such as paclitaxel (Taxol™, Bristol-Myers Squibb Oncology, Princeton, NJ) and docetaxel (Taxotere™, Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitors RFS2000; difluoromethylornithine (DMFO); retinoic acid; esperamicin;and capecitabine; and pharma- ceutically acceptable salts, acids, or derivatives of any of the above.
[0118] In certain aspects, the metastatic breast cancer comprises metastatic triple-negative breast cancer and the method comprises administering leronlimab in combination with doxorubicin or leronlimab in combination with carboplatin.
[0119] In one embodiment, the present disclosure provides a method of treating or preventing CCR5-positive metastatic breast cancer, comprising administering to a subject in need thereof an effective amount of a CCR5-binding agent.
[0120] In a further embodiment, the CCR5 binding agent competes with CCL5 for binding to the CCR5 cell receptor. In a further embodiment, the CCR5 binding agent comprises monoclonal antibody PA14, leronlimab, or CCR5mAb004, or a binding fragment thereof. In a further embodiment, the competitive inhibitor competes with monoclonal antibody PA14, leronlimab, or CCR5mAb004, or a binding fragment thereof for binding.
[0121] In one embodiment, the disclosure provides a method of treating or preventing CCR5-positive metastatic breast cancer comprising administering leronlimab, or a binding fragment thereof, to a subject in need thereof.
[0122] In any of the foregoing aspects, preventing metastatic breast cancer can include slowing the growth or spread of cancer metastases or primary tumors, preventing the formation of metastatic tumors, or limiting or reducing the growth or size of metastatic tumors or primary tumors.
[0123] In one embodiment, the CCR5 binding agent, such as leronlimab, is administered with a pharma- ceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those skilled in the art. Such pharma- ceutically acceptable carriers can include, but are not limited to, aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, saline, and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, Ringer's lactate, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as antimicrobial agents, antioxidants, chelating agents, inert gases, and the like. In one embodiment, the CCR5 binding agent is provided in a formulation as disclosed in US Patent No. 9,956,165, the contents of which are incorporated herein by reference.
[0124] The dose of the composition of the present disclosure will vary depending on the subject and the specific administration route used. The dose can range from 0.1 to 100,000 μg / kg. Depending on the composition, the dose can be delivered continuously, for example by a continuous pump, or at regular intervals, for example at one or more separate times. The desired time interval between multiple doses of a particular composition can be determined by one of ordinary skill in the art without undue experimentation.
[0125] In one embodiment of the method, the antibody or binding fragment thereof is administered to the subject multiple times, with each administration delivering 0.01 mg / kg to 50 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers 0.05 mg / kg to 25 mg / kg of antibody or binding fragment thereof to the subject. In a further embodiment, each administration delivers 0.1 mg / kg to 10 mg / kg of antibody or binding fragment thereof to the subject. In yet a further embodiment, each administration delivers 0.5 mg / kg to 5 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers 1 mg / kg to 3 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers about 2 mg / kg of antibody or binding fragment thereof to the subject. Embodiments include dosage amounts ranging from about 175 mg to about 1,400 mg, including dosage forms that deliver amounts of CCR5 binding agent, for example, 175 mg, 350 mg, 525 mg, 700 mg, 875 mg, 1050 mg, 1,225 mg, and 1,400 mg.
[0126] In one embodiment, the antibody or binding fragment thereof is administered multiple times, the first administration being spaced apart from the subsequent administration by an interval of less than one week. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of at least one week. In a further embodiment, the first administration is spaced apart from the subsequent administration by an interval of one week. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of two to four weeks. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of two weeks. In a further embodiment, the first administration is spaced apart from the subsequent administration by an interval of four weeks. In yet another embodiment, the antibody or binding fragment thereof is administered multiple times, the first administration being spaced apart from the subsequent administration by an interval of at least one month.
[0127] In a further aspect, the antibody or binding fragment thereof is administered to the subject by intravenous infusion. In another aspect, the antibody or binding fragment thereof is administered to the subject by subcutaneous injection. In another aspect, the antibody or binding fragment thereof is administered to the subject by intramuscular injection.
[0128] In one embodiment, the method may further comprise administering to the subject a cell therapy, such as an autologous or allogeneic immunotherapy; a small molecule; a chemotherapeutic agent; or an inhibitor of CCR5 / CCL5 signaling. In one embodiment, an inhibitor of CCR5 / CCL5 signaling is administered, and comprises maraviroc, vicriviroc, aplaviroc, SCH-C, TAK-779, PA14 antibody, 2D7 antibody, RoAb13 antibody, RoAb14 antibody, or 45523 antibody.
[0129] In one embodiment, a competitive inhibitor for the CCR5 cell receptor, such as PRO140, is administered in combination with one or more other therapeutic molecules or treatments, such as a cell therapy, such as autologous or allogeneic immunotherapy; a small molecule; chemotherapy; or an inhibitor of CCR5 / CCL5 signaling, such as maraviroc, vicriviroc, aplaviroc, SCH-C, TAK-779, PA14 antibody, 2D7 antibody, RoAb13 antibody, RoAb14 antibody, or 45523 antibody. In one embodiment, the methods disclosed herein include administering PRO140 in combination with maraviroc, vicriviroc, aplaviroc, SCH-C, TAK-779, PA14 antibody, 2D7 antibody, RoAb13 antibody, RoAb14 antibody, or 45523 antibody.
[0130] In one embodiment, a CCR5 binding agent such as PRO140 is administered in combination with one or more chemotherapy agents, such as, for example: alkylating agents, such as thiotepa and cyclosphosphamide; alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, metholedopa, and uredopa; altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethio ... ethylenimines and methylamelamines, including methyl melamine, ethylenimines such as methyl melamine, ethylenimines such as ethylenimines, ... uracil mustard; nitrosurea, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics, such as aclacinomycin, actinomycin, anthramycin, azaserine, bleomycin, cactinomycin, calicheamicin, carabicin, caminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, cin, epirubicin, esorubicin, idarubicin, marcelomycin, mitomycin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfilomycin, puromycin, keramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites, such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs, such as denopterin, methotrexate, pteropterin, and trimetrexate;Purine analogues, such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogues, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, and 5-FU; androgens, such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, and testolactone; antiadrenal drugs, such as aminoglutethimide, mitotane, and trilostane; folic acid supplements, such as folinic acid acid);aceglatone;aldophosphamide glycosides;aminolevulinic acid;amsacrine;bestrabucil;bisantrene;edatrexate;defofamine;demecolcine;diazicon;elformitine;elliptinium acetate;ethoglucide;gallium nitrate;hydroxyurea;lentinan;lonidamine;mitoguazone;mitoxantrone;mopidamol;nitracrine;pentostatin;phenamet;pirarubicin;podophyllic acid;2-ethyline hydrazide; procarbazine; PSK™; razoxane; schizofiran; spirogermanium; tenuazonic acid; triazicon; 2,2',2''-trichlorotriethylamine; urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, such as paclitaxel (Taxol™, Bristol-Myers Squibb Oncology, Princeton, NJ) and docetaxel (Taxotere™, Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitors RFS2000; difluoromethylornithine (DMFO); retinoic acid; esperamicin;and capecitabine; and pharma- ceutically acceptable salts, acids, or derivatives of any of the above.
[0131] "Small molecule" CCR5 receptor antagonist as used herein includes, for example, small organic molecules that bind to CCR5 receptor and inhibit the activity of the receptor.In one embodiment, the small molecule has a molecular weight of less than 1,500 daltons.In another embodiment, the small molecule has a molecular weight of less than 600 daltons.
[0132] In one embodiment, a CCR5 binding agent such as PRO140 is administered in combination with one or more small molecules, such as SCH-C (Strizki et al., PNAS, 98: 12718-12723 (2001)); SCH-D (SCH417670; vicriviroc); UK-427,857 (maraviroc; 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl-4-methylpiperidine); GW873140; TAK-652; TAK-779; AMD070; AD101; 1,3,4-trisubstituted pyrrolidines (Kim et al., Bioorg. Med. Chem. Lett., 15: 2129-2134 (2005)); modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butanes (Shah et al., Bioorg. Med. Chem. Lett., 15: 977-982 (2005)); anibamine TFA, ophiobolin C, or 19,20-epoxycytochalasin Q (Jayasuriya et al., J. Nat. Prod., 67: 1036-1038 (2004)); 5-(piperidin-1-yl)-3-phenyl-pentylsulfone (Shankaran et al., Bioorg. Med. Chem. Lett., 14: 3589-3593 (2004)); 4-(heteroarylpiperzin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists (Shankaran et al., Bioorg. Med. Chem. Lett., 14: 3419-3424 (2004)); agents containing a 4-(pyrazolyl)piperidine side chain (Shu et al., Bioorg. Med. Chem. Lett., 14: 947-52 (2004);Shen et al., Bioorg. Med. Chem. Lett., 14: 935-939 (2004);Shen et al., Bioorg. Med. Chem. Lett., 14: 941-945 (2004)); 3-(pyrrolidin-1-yl)propionic acid analogs (Lynch et al., Org. Lett., 5: 2473-2475 (2003);[2-(R)-[N-methyl-N-(1-(R)-3-(S)-((4-(3-benzyl-1-ethyl-(1H)-pyrazol-5-yl)piperidin-1-yl)methyl)-4-(S)-(3-fluorophenyl)cyclopent-1-yl)amino]-3-methylbutanoic acid (MRK-1)] (Kumar et al., J. Pharmacol. Exp. Then, 304: 1161-1171 (2003));1,3,4 trisubstituted pyrrolidines with 4-aminoheterocycle-substituted piperidine side chains (Willoughby et al., Bioorg. Med. Chem. Lett., 13: 427-431 (2003);Lynch et al., Bioorg. Med. Chem. Lett., 12: 3001-3004 (2003);Lynch et al., Bioorg. Med. Chem. Lett., 13: 119-123 (2003);Hale et al., Bioorg. Med. Chem. Lett., 12: 2997-3000 (2002)) Combinatorial synthesis of CCR5 antagonists (Willoughby et al., Bioorg. Med. Chem. Lett., 11: 3137-41 (2001)); Heterocycle-containing compounds (Kim et al., Bioorg. Med. Chem. Lett., 11: 3103-3106 (2001)); hydantoin-containing antagonists (Kim et al., Bioorg. Med. Chem. Lett., 11: 3099-3102 (2001)); 1,3,4 trisubstituted pyrrolidines (Hale et al., Bioorg. Med. Chem. Lett., 11: 2741-2745 (2001)); 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes (Finke et al., Bioorg. Med. Chem.Lett., 11: 2475-2479 (2001)); compounds from the plant Lippia alba (Hedge et al., Bioorg. Med. Chem. Lett., 12: 5339-5342 (2004)); piperazine-based CCR5 antagonists (Tagat et al., J. Med. Chem., 47: 2405-2408 (2004)); oxyimino-piperidino-piperidine-based CCR5 antagonists (Palani et al., Bioorg. Med. Chem. Lett., 13: 709-712 (2003)); rotamers of SCH 351125 (Palani et al., Bioorg. Med. Chem. Lett., 13: 705-708 (2003)); symmetrical heteroaryl carboxamides based on piperazine (McCombie et al., Bioorg. Med. Chem. Lett., 13: 567-571 (2003)); oxyimino-piperidino-piperidine amides (Palani et al., J. Med. Chem., 45: 3143-3160 (2002)); Sch-351125 and Sch-350634 (Este, Curr. Opin. Investig. Drugs., 3: 379-383 (2003)); (2002));1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[l(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-oxide (Sch-350634) (Tagat et al., J. Med. Chem., 44: 3343-3346 (2001));4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine N-oxide (SCH351125) (Palani et al., J. Med. Chem., 44: 3339-3342 (2001));2(S)-methylpiperazine (Tagat et al., Bioorg. Med. Chem. Lett., 11: 2143-2146 (2001)); piperidine-4-carboxamide derivatives (Imamura et al., Bioorg. Med. Chem., 13: 397-416, 2005); 1-benzazepine derivatives containing a sulfoxide moiety (Seto et al., Bioorg. Med. Chem. Lett., 13: 363-386 (2005)); anilide derivatives containing a pyridine N-oxide moiety (Seto et al., Chem. Pharm. Bull. (Tokyo), 52: 818-829 (2004)); 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety (Seto et al., Chem. Pharm. Bull. (Tokyo), 52: 577-590 (2005)). (2004));N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylurea (Imamura et al., Bioorg. Med. Chem., 12: 2295-2306 (2004));5-oxopyrrolidine-3-carboxamide derivatives (Imamura et al., Chem. Pharm. Bull. (Tokyo), 52: 63-73 (2004);anilide derivatives with quaternary ammonium moieties (Shiraishi et al., J. Med. Chem., 43: 2049-2063 (2000));AK602 / ONO4128 / GW873140 (Nakata et al., J. Virol., 79: 2087-2096 (2005));spirodiketopiperazine derivatives (Maeda et al., J. Biol. Chem., 276: 35194-35200 (2001);Maeda et al., J. Virol., 78: 8654-8662 (2004)); and selective CCR5 antagonists (Thoma et al., J. Med. Chem., 47: 1939-1955 (2004)).
[0133] In one embodiment, a CCR5 binding agent such as PRO140 is administered in combination with one or more of SCH-C, SCH-D (SCH417670 or vicriviroc), UK-427,857 (maraviroc), GW873140, TAK-652, TAK-779, AMD070, or AD101. See US Pat. No. 8,821,877.
[0134] In one embodiment, competitive binding agents for the CCR5 cell receptor, such as PRO140, exhibit synergistic effects when administered in combination with a DNA damaging agent. In a further embodiment, competitive binding agents for the CCR5 cell receptor, such as PRO140, exhibit synergistic effects when administered in combination with a DNA damaging agent and in conjunction with one or more other therapeutic molecules or treatments, such as cell therapy, small molecules, chemotherapy, or inhibitors of CCR5 / CCL5 signaling.
[0135] "Synergy" between two or more drugs refers to a combined effect of the drugs that is greater than their additive effect. Synergistic, additive, or antagonistic effects between drugs can be quantified by analysis of dose-response curves using the combination index (CI) method. A CI value greater than 1 indicates antagonism; a CI value equal to 1 indicates an additive effect; a CI value less than 1 indicates a synergistic effect. In one embodiment, the CI value of a synergistic interaction is less than 0.9. In another embodiment, the CI value is less than 0.8. In another embodiment, the CI value is less than 0.7.
[0136] In any of the foregoing aspects, preventing cancer can include slowing the growth of cancer, preventing the formation of a tumor, or limiting or reducing the growth or size of a tumor.
[0137] In one embodiment, the competitive inhibitor for the CCR5 cell receptor, such as PRO140, is administered with a pharma- ceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those skilled in the art. Such pharma- ceutically acceptable carriers can include, but are not limited to, aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, saline, and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, Ringer's lactate, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as antimicrobial agents, antioxidants, chelating agents, inert gases, and the like.
[0138] The dose of the composition of the present disclosure will vary depending on the subject and the specific administration route used. The dose can range from 0.1 to 100,000 μg / kg. Depending on the composition, the dose can be delivered continuously, for example by a continuous pump, or at regular intervals, for example at one or more separate times. The desired time interval between multiple doses of a particular composition can be determined by one of ordinary skill in the art without undue experimentation.
[0139] In one embodiment of the method, the antibody or binding fragment thereof is administered to the subject multiple times, with each administration delivering 0.01 mg / kg to 50 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers 0.05 mg / kg to 25 mg / kg of antibody or binding fragment thereof to the subject. In a further embodiment, each administration delivers 0.1 mg / kg to 10 mg / kg of antibody or binding fragment thereof to the subject. In yet a further embodiment, each administration delivers 0.5 mg / kg to 5 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers 1 mg / kg to 3 mg / kg of antibody or binding fragment thereof to the subject. In another embodiment, each administration delivers about 2 mg / kg of antibody or binding fragment thereof to the subject.
[0140] In one embodiment, the antibody or binding fragment thereof is administered multiple times, the first administration being spaced apart from the subsequent administration by an interval of less than one week. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of at least one week. In a further embodiment, the first administration is spaced apart from the subsequent administration by an interval of one week. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of two to four weeks. In another embodiment, the first administration is spaced apart from the subsequent administration by an interval of two weeks. In a further embodiment, the first administration is spaced apart from the subsequent administration by an interval of four weeks. In yet another embodiment, the antibody or binding fragment thereof is administered multiple times, the first administration being spaced apart from the subsequent administration by an interval of at least one month.
[0141] In a further aspect, the antibody or binding fragment thereof is administered to the subject by intravenous infusion. In another aspect, the antibody or binding fragment thereof is administered to the subject by subcutaneous injection. In another aspect, the antibody or binding fragment thereof is administered to the subject by intramuscular injection.
[0142] In one embodiment, the method may further comprise administering to the subject a cell therapy, such as an autologous or allogeneic immunotherapy; a small molecule; a chemotherapeutic agent; or an inhibitor of CCR5 / CCL5 signaling. In one embodiment, an inhibitor of CCR5 / CCL5 signaling is administered, and comprises maraviroc, vicriviroc, aplaviroc, SCH-C, TAK-779, PA14 antibody, 2D7 antibody, RoAb13 antibody, RoAb14 antibody, or 45523 antibody.
[0143] In one embodiment, a competitive inhibitor for the CCR5 cell receptor, such as PRO140, is administered in combination with one or more other therapeutic molecules or treatments, such as a cell therapy, such as autologous or allogeneic immunotherapy; a small molecule; chemotherapy; or an inhibitor of CCR5 / CCL5 signaling, such as maraviroc, vicriviroc, aplaviroc, SCH-C, TAK-779, PA14 antibody, 2D7 antibody, RoAb13 antibody, RoAb14 antibody, or 45523 antibody. In one embodiment, the methods disclosed herein include administering PRO140 in combination with maraviroc, vicriviroc, aplaviroc, SCH-C, TAK-779, PA14 antibody, 2D7 antibody, RoAb13 antibody, RoAb14 antibody, or 45523 antibody.
[0144] Although the study described herein concerns breast cancer cell line studies, it is contemplated that other cancers expressing CCR5 may also benefit from the use of leronlimab or other anti-CCR5 agents to block metastasis and / or enhance cell death induced by DNA-damaging chemotherapy. Such other cancers may include, but are not limited to, leukemia cancer, lymphoma cancer, bone and connective tissue sarcoma, brain cancer, breast cancer, adrenal cancer, pancreatic cancer, stomach cancer, colon cancer, prostate cancer, rectal cancer, gallbladder cancer, lung cancer, oral cancer, skin cancer, kidney cancer, and osteogenic sarcoma cancer, and other cancers.
[0145] Anti-CCR5 agents can include, but are not limited to, antibodies, other proteins, and small molecule agents such as maraviroc and vicriviroc.
[0146] DNA damage chemotherapy drugs can include, but are not limited to, anthracycline, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, and amethantrone, and any of their derivatives.Other chemotherapy drugs, such as carboplatin, cisplatin, cyclophosphamide, docetaxel, erlotinib, etoposide, fluorouracil, gemcitabine, imatinib mesylate, irinotecan, methotrexate, paclitaxel, sorafinib, sunitinib, topotecan, vincristine, or vinblastine, and others, can be used in the present disclosure and can benefit from the present disclosure.It is contemplated that any conventional therapeutic agent for use in treating cancer or cancer metastasis can be used together with the present disclosure and can benefit from the present disclosure.
[0147] DNA-damaging drugs Without being bound by theory, it is believed that exposure of cancer cells to certain DNA damaging agents results in sufficient DNA damage to induce a DNA damage response and a temporary S-phase arrest to allow DNA repair. The DNA damage response is believed to be controlled by two homologous protein kinases, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia Rad3-related (ATR). ATR signals to control DNA replication, cell cycle transition, and DNA repair by phosphorylating hundreds of substrates, including checkpoint kinase 1 (Chk1). DNA damaging agents have a long history of use in cancer chemotherapy. DNA damage induces cellular apoptosis, which is widely believed to be the primary antiproliferative mechanism of DNA damaging anticancer drugs. EXAMPLES
[0148] Example 1. Binding of Leronlimab to CCR5 expressed by breast cancer cells Figures 1A and 1B. Leronlimab binds to CCR5 on human breast cancer cells.
[0149] As shown in Figure 1A, to determine the binding of leronlimab to human CCR5 in breast cancer cells, MDA-MB-231 human breast cancer cell line was transfected with human CCR5 expression vector as a model system. A previously tested commercial APC-conjugated mouse anti-human / mouse / rat CCR5 antibody (FAB1802A) from R&D (APC-αCCR5) was used as a positive control to evaluate CCR5 positive cells. MDA-MB-231-CCR5 cells were stained with both APC-αCCR5 and leronlimab using concentrations of 1-140 μg / ml. Alexa Fluor 488-conjugated mouse anti-human IgG was used as the secondary antibody to measure leronlimab-bound cells. Analysis of leronlimab binding to CCR5 by FACS is shown in Figure 1A. The binding of leronlimab to human CCR5 was verified.
[0150] As shown in Fig. 1B , the efficiency of PR140 binding to CCR5-positive cells was up to 98%.
[0151] Example 2. CCL5-induced Ca in MDA-MB-231-CCR5 cells 2+ Effect of PR140 on the response Figure 2A, Figure 2B, Figure 2C, and Figure 2D. PR140 (leronlimab) blocks signaling mediated by human CCR5 in human breast cancer cells. CCR5 activation induces calcium flux (Mueller et al., 2002; Petkovic et al., 2004). To evaluate the effect of leronlimab on CCR5 function, we measured the calcium response induced by CCL5 in MDA-MB-231-CCR5 cells by live cell imaging with or without leronlimab (Figure 2A, Figure 2B, and Figure 2C). Fluo-4 was used as a calcium concentration indicator. The CCR5 antagonist vicriviroc was used as a positive control (Figure 2A and 2D). The results showed that leronlimab could block the CCL5-induced calcium response in MDA-MB-231-CCR5 cells (1.23±0.10, N=10 in control cells, 0.54±0.13, N=12 in PR140-treated cells; P<0.001 for CCL5-induced calcium peak).
[0152] Example 3. Leronlimab blocks breast cancer cell invasion into 3D Matrigel Figure 3A, Figure 3B, Figure 3C, and Figure 3D. Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into extracellular matrix. The ability of breast cancer cells to invade extracellular matrix is a key step in what can be distinguished from tumor metastasis (Zetter, 1990). To test the ability of PRO140 to block 3D Matrigel invasion assay, MDA-MB-231 cells were used. CCL5 was used as a chemoattractant to induce invasion. Vicriviroc, a small molecule inhibitor of CCR5, was used as a form of positive control. Leronlimab reduced CCL5-induced MDA-MB-231 breast cancer cell invasion with a similar potency as Vicriviroc (Figure 3A, Figure 3B) (control 855±9, N=8 vs. Leronlimab 855±9, N=9. P<0.001). We also tested the effects of different doses of leronlimab on breast cancer cell invasion, and the results showed that both 175 and 350 μg / ml of leronlimab could effectively block MDA-MB-231 cell invasion (FIG. 3C, D).
[0153] Example 4. Leronlimab blocks breast cancer cell metastasis in a mouse lung metastasis model Figure 4A and Figure 4B. Leronlimab blocks breast cancer metastasis in mice. Mice were randomly divided into four groups (control, leronlimab, maraviroc, and vicriviroc). Stable MDA-MB-231 cells transfected with Luc2-GFP were injected into the mice via the tail vein. Mice in each group were treated one day before injection. Metastatic tumors formed in the lungs were determined by bioluminescence imaging. Bioluminescence images of representative mice from the control, leronlimab, and maraviroc groups were shown in (Figure 4A). Quantitative analysis of tumor size in each group was shown in (Figure 4B). Tumor size was measured using photon flux (×10 8 p / sec / cm 2 Data are presented as mean ± SE. Leronlimab dramatically reduced breast cancer tumor metastasis to the lungs.
[0154] Example 5. Leronlimab enhances cell death induced by doxorubicin Figure 5A and Figure 5B. Leronlimab enhances cell death induced by the DNA damage-inducing chemotherapy drug doxorubicin. MDA-MB-231 cells were treated with 10 mg / ml leronlimab in combination with different doses of doxorubicin for 3 days. Relative cell numbers were determined using an MTT assay (Figure 5A). Cells treated with maraviroc (100 mM) in combination with different doses of doxorubicin were used as positive controls (Figure 5B). Data are shown as mean ± SEM of N=8.
[0155] Example 6. Leronlimab and carboplatin treatment for CCR5+ metastatic TNBC Here, we describe preliminary results from a phase Ib / II study of leronlimab (PRO140) in combination with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC). The primary objective of phase 1b is to determine the safety, tolerability, and maximum tolerated dose (MTD) of PRO140 in patients with TNBC when combined with carboplatin to define a recommended phase II dose of the combination. The primary objective of phase 2b is to evaluate the impact of the combination PRO140 and carboplatin on progression-free survival (PFS) in patients with CCR5+ TNBC previously treated with anthracyclines and taxanes in the neoadjuvant and adjuvant settings.
[0156] The first subject enrolled in the study, subject 706-001, is a 42-year-old woman with stage IV metastatic triple-negative breast cancer. The subject has a history of left breast cancer and right lung metastasis.
[0157] The patient was diagnosed with stage IIA grade 3 invasive ductal carcinoma (ER neg / PR neg / HER-2-NEU neg) and had previously received dose-dense doxorubicin-cyclophosphamide [ddAC] and paclitaxel. The patient underwent left breast lumpectomy and sentinel lymph node biopsy 3 weeks after diagnosis.
[0158] Subjects signed informed consent for prescreening with protocol CD07_TNBC 10 weeks after diagnosis. Immunohistochemistry analysis of archival tissue showed a high predominance of CCR5+ tumor-infiltrating leukocytes (Figures 6A-6C).
[0159] The baseline target lesion was identified in the upper right lung, measuring 25 mm in size. The lesion was described as a large interlobar soft tissue density nodule based on the pleura in the right hilar region.
[0160] Approximately 6 weeks after baseline lesion identification and measurement, subjects received their first treatment of 350 mg leronlimab (PRO140) (1). Each treatment cycle consisted of 21 days. Leronlimab (PRO140) was administered subcutaneously on days 1, 8, and 15 of each week in combination with carboplatin AUC5 on day 1 of each cycle (every 21 days). Unless otherwise indicated, this treatment regimen was used for all subjects enrolled in mTNBC studies.
[0161] [Table 1]
[0162] Blood samples for circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAMLs) evaluation were collected at baseline and then on day 1 of each treatment cycle to evaluate changes in CTCs and CAMLs after treatment and to perform correlation analysis between CCR5 expression and PD-L1 expression.
[0163] Creatv Microtech is developing a size-based technology and detection methodology (LifeTrac assay) that allows for the collection and characterization of all cancer-related cells in blood, namely CTCs, epithelial-mesenchymal transition cells (EMT), and CAMLs [Adams Cytometry 2015, Adams RSC 2014]. The CellSieve™ filtration platform is used to capture CAMLs and CTCs.
[0164] A summary of the results for CCR5 and PD-L1 expression is as follows:
[0165] [Table 2]
[0166] A summary of the total CTC, EMT, and CAML results is as follows:
[0167] [Table 3]
[0168] Scans were taken at the end of every 2 cycles (every 6 weeks). Subjects had scan 1 after 6 weeks, scan 2 after 12 weeks, and scan 3 after 18 weeks (Table 4). No new lung nodules were found in scan 3. The target lesion found in the right upper lobe of the lung nodule measured 2.1 x 1.6 cm, previously 2.4 x 1.9, with a 20% reduction in size.
[0169] [Table 4]
[0170] The right pulmonary metastasis demonstrated a maximum standard uptake value (SUV) of 6.8 (previously 15.3). The previously identified right hilar lymph node had resolved. No new lymphadenopathy or metastatic disease was reported in the chest, abdomen, and pelvis on diagnostic CT.
[0171] At the time the subject completed the Cycle 6 Day 1 visit, the subject was receiving weekly injections of leronlimab (PRO140) and carboplatin infusions every 3 weeks per protocol. At the time of the Cycle 6 Day 1 visit, no serious adverse events were reported.
[0172] After 16 weeks of leronlimab treatment, the first subject enrolled in the mTNBC study showed no detectable circulating tumor cells (CTCs) or putative metastatic tumor cells in the peripheral blood. Furthermore, the patient had a large reduction in CCR5 expression on cancer-associated cells after approximately 11 weeks of treatment with leronlimab. In addition, the target lesion found in the right upper lobe of the lung nodule shows a greater than 20% reduction in size (measured by tumor volume). This result is a significant improvement in disease outcome, demonstrating that leronlimab is a promising adjuvant therapy for the treatment of metastatic triple-negative breast cancer.
[0173] A second subject with mTNBC was enrolled in the mTNBC study. Data collected from the second patient enrolled in the Company's mTNBC Phase 1b / 2 trial showed no detectable levels of CTCs after two weeks of treatment with the previously described treatment regimen of leronlimab in combination with carboplatin. This patient also showed a 70% reduction in EMT cells after only two weeks of treatment. Initial data from the second patient in the mTNBC trial indicated that CTCs had dropped to zero after two weeks of treatment with leronlimab. In addition, the second patient had an initial CAML count of 45, and after at least two weeks of treatment, the CAML count had decreased to 30.
[0174] A third subject was enrolled in the mTNBC study. CTC+EMT counts were measured at the start of treatment with the treatment regimen described above and two weeks after the start of treatment. Results showed that the total CTC+EMT counts of the third patient were reduced by 75% during the first two weeks of treatment.
[0175] The various embodiments described above can be combined to provide further embodiments.All US patents, US patent application publications, US patent applications, foreign patents, foreign patent applications, and non-patent publications referenced herein and / or listed in the application data sheet, including US Provisional Patent Application No. 62 / 827,729 filed April 1, 2019, are incorporated herein by reference in their entirety.When necessary, aspects of the embodiments can be modified to adopt the concepts of various patents, applications, and publications to provide still further embodiments.
[0176] These and other changes can be made to the embodiments in light of the above detailed description. In general, the terms used in the following claims should not be construed to limit the claims to the specific embodiments disclosed in the specification and claims, but rather to encompass all possible embodiments along with the full scope of equivalents to which such claims are entitled. Thus, the claims are not limited by this disclosure.
Claims
1. 1. Use of a combination of an anti-CCR5 agent and a DNA damaging agent in the manufacture of one or more medicaments for treating or preventing CCR5+ cancer metastasis, wherein the CCR5+ cancer is CCR5+ metastatic triple-negative breast cancer, the anti-CCR5 agent is leronlimab or a fragment of leronlimab that recognizes and binds to an epitope on the CCR5 chemokine receptor, and the DNA damaging agent is selected from one of doxorubicin, carboplatin, daunorubicin, epirubicin, idarubicin, mitoxantrone, and amethantrone.
2. 2. The use according to claim 1, wherein the DNA damaging agent is carboplatin.
3. 1. Use of an anti-CCR5 agent in the manufacture of a medicament for prolonging the effectiveness of DNA damaging chemotherapy for the treatment or prevention of CCR5+ cancer metastasis, wherein the CCR5+ cancer is CCR5+ metastatic triple-negative breast cancer, the anti-CCR5 agent is leronlimab or a fragment of leronlimab that recognizes and binds to an epitope on the CCR5 chemokine receptor, and the DNA damaging chemotherapy comprises administration of a DNA damaging agent selected from one of doxorubicin, carboplatin, daunorubicin, epirubicin, idarubicin, mitoxantrone, and amethantrone.
4. 4. The use according to claim 3, wherein the DNA damaging agent is carboplatin.
5. A composition for the treatment or prevention of metastasis of a CCR5+ cancer, characterized by comprising an anti-CCR5 agent and an agent for DNA damaging chemotherapy, wherein the CCR5+ cancer is a CCR5+ metastatic triple negative breast cancer, the anti-CCR5 agent is leronlimab or a fragment of leronlimab that recognizes and binds to an epitope on the CCR5 chemokine receptor, and the agent for DNA damaging chemotherapy is selected from one of doxorubicin, carboplatin, daunorubicin, epirubicin, idarubicin, mitoxantrone, and amethantrone.
6. The composition of claim 5, wherein the agent for DNA damaging chemotherapy is carboplatin.
